Inovio Pharmaceuticals (INO) Competitors

Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Does the media refer more to INO or MRNA?

In the previous week, Moderna had 17 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 22 mentions for Moderna and 5 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.57 beat Inovio Pharmaceuticals' score of 0.52 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	12 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Is INO or MRNA more profitable?

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-163.32%	-96.41%
Moderna	-94.31%	-25.96%	-20.09%

Do analysts recommend INO or MRNA?

Inovio Pharmaceuticals currently has a consensus price target of $8.80, indicating a potential upside of 348.98%. Moderna has a consensus price target of $42.88, indicating a potential upside of 58.12%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Do institutionals & insiders believe in INO or MRNA?

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 2.3% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has higher valuation and earnings, INO or MRNA?

Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$220K	473.43	-$107.25M	-$2.61	-0.75
Moderna	$3.06B	3.45	-$3.56B	-$7.53	-3.60

Which has more volatility & risk, INO or MRNA?

Inovio Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.

Summary

Moderna beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.